ImmuCell Corp（ICCC）資訊與事件ICCCImmuCell Corp

ImmuCell Q2 Sales Increase 11.5% to $7.2 Million

"Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025," said Timothy Fiori, CFO of ImmuCell. "Our growth in the second quarter is particularly significant given the challenging comparison with the second quarter of 2025, when ImmuCell recorded substantial sales from distributors replenishing inventory following an extended period of backorders. International sales in the three months ended June 30, 2026 declined $0.6 million, or 38.9% compared to 2025; however, we believe that end-customer demand remains strong, particularly in Canada. Total sales for the six months ended June 30, 2026 were $17.5 million, a 20.9% increase compared to the six months ended June 30, 2025."

ImmuCell Reports Preliminary FY25 Revenue of $27.6M

Reports preliminary FY25 revenue $27.6M. "Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges," commented Olivier te Boekhorst, president and CEO of ImmuCell. "This was one of our highest sales quarters ever, without tailwinds from catching up on backorders. Our international business showed a decline, largely due to order timing. We are highly encouraged by the strong growth of our Tri-Shield product line, which reflects the migration from Dual-Force products and the acquisition of new dairy and beef customers seeking protection for their calves."

ImmuCell Pauses Re-Tain Investment, Increases First Defense Sales Force by 50%

ImmuCell Corporation announced that it received an Incomplete Letter from the FDA on December 23 for its Re-Tain New Animal Drug Application, or NADA, and simultaneously that it is increasing its First Defense field sales force by 50% and expanding its First Defense manufacturing capabilities. In seeking FDA approval to bring its innovative Re-Tain product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It pursued a two-pronged manufacturing approach to reduce capital expenditure and limit technical risk for the remaining fifth Technical Section pertaining to manufacturing. ImmuCell manufactured the active pharmaceutical ingredient using a proprietary process in its own facility and hired an experienced contract manufacturer with FDA approvals for animal health products for the aseptic filling of the product into syringes. ImmuCell passed FDA inspection of its own facility in 2024. It is ImmuCell's understanding that the FDA is now declining to approve the NADA because the contract manufacturer has not satisfactorily addressed inspectional deficiencies. After considering the practical implications of the resulting delays, including the pending expiration of ImmuCell's contract with the manufacturer in March 2026, ImmuCell has decided to pause further investment in Re-Tain and increase its investment in its market leading First Defense franchise, which it believes to have significant revenue and profit growth capacity. ImmuCell will complete ongoing investigational studies with Re-Tain to assess opportunities for an improved set of claims for preventing and treating mastitis in dairy cows. It will seek to license the product to interested parties or, depending on the outcome of the studies, may seek to partner with a global manufacturer. Neither approach would require further capital investment or in-house manufacturing capability, meaning that ImmuCell will prioritize cash and other resources for maximizing the value of its market leading First Defense franchise.